Anneleis F. Willett

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial”.

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-004822

N/A

1.4DataRank · unranked

44 citations

Bettzy Stephen, Daniel D. Karp, Sarina A. Piha‐Paul, David S. Hong, D Jain +10 more

Comprehensive genomic profiling of malignant peritoneal mesothelioma (MPeM) reveals key genomic alterations (GAs) distinct from malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8557

N/A

0.104DataRank · unranked

1 citations

Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu, Anaís Malpica +13 more

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0331

N/A

0DataRank · unranked

73 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu-Chin Fu +29 more

Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad095

N/A

0DataRank · unranked

21 citations

Aakash Tushar Shah, Honey V. Reddi, Priyadarsini Dasari, James T. Topham, Hyunsoo Hwang +16 more

Data from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma

(2023)10.1158/2159-8290.c.6549433.v1

N/A

0DataRank · unranked

0 citations

Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu‐Chin Fu +29 more

Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0019

N/A

0DataRank · unranked

11 citations

Mohammad A. Zeineddine, Betul Beyza Gunes, Andrew J. Pellatt, Mark Knafl, Haifeng Zhu +12 more